Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 1M | 608K | 254K | 223K | 1M |
| Gross Profit | 224K | 223K | -221K | -209K | 310K |
| Operating Income | -8M | -10M | -5M | -2M | -1M |
| EBITDA | -7M | -8M | -1M | -2M | -1M |
| Net Income | -7M | -8M | -4M | -6M | -4M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$1.64
+1.23% today
1Y Change
-80.93%
Window
Jun 23, 2025 → Jun 18, 2026
Coverage: 249 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
60 Degrees Pharmaceuticals, Inc. (SXTP) is a Healthcare stock with listed on NASDAQ. The stock last traded around $1.64 and down 80.9% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of +65.5%, EPS growth of +84.2%, a dividend yield of 0.0%. What stands out right now is revenue +65.5%, EPS +84.2%, free cash flow -21.2% with operating margin -771.6% and ROIC -219.7%. Valuation is more restrained than many high-expectation growth names at price/sales 1.3. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines SXTP price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SXTP
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SXTP Max Drawdown
-86.97%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SXTP and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$1.2M
+419.8% YoY
FY Net Income
-$4.3M
+31.2% YoY
Free Cash Flow
-$684.5K
+36.0% YoY
Revenue Growth
+65.5%
EPS Growth
+84.2%
Gross Margin
22.3%
Net Margin
-732.8%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 1M | 608K | 254K | 223K | 1M |
| Gross Profit | 224K | 223K | -221K | -209K | 310K |
| Operating Income | -8M | -10M | -5M | -2M | -1M |
| EBITDA | -7M | -8M | -1M | -2M | -1M |
| Net Income | -7M | -8M | -4M | -6M | -4M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 2M | 2M | 2M | 265K | 115K |
| Total Assets | 5M | 6M | 8M | 1M | 1M |
| Total Liabilities | 2M | 2M | 3M | 25M | 20M |
| Shareholder Equity | 3M | 4M | 5M | -24M | -18M |
| Total Debt | 153K | 156K | 173K | 22M | 19M |
| Net Debt | -1M | -2M | -2M | 22M | 19M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
649K
+35.7% YoY
Capital Expenditures
35K
+41.1% YoY
Free Cash Flow
684K
+36.0% YoY
Key ratios
Gross Margin
22.3%
Operating Margin
-771.6%
Net Margin
-732.8%
ROE
-204.2%
Debt / Equity
0.04x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.